Two Models of Legalization of Psychedelic Substances
Open Access
- 24 August 2021
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 326 (8), 697-698
- https://doi.org/10.1001/jama.2021.12481
Abstract
This Viewpoint reviews legalization initiatives for psychedelic substances and the concerns they raise by looking to the cautionary precedents involving the legKeywords
This publication has 12 references indexed in Scilit:
- Faculty Opinions recommendation of Trial of Psilocybin versus Escitalopram for Depression.Published by H1 Connect ,2021
- Trial of Psilocybin versus Escitalopram for DepressionThe New England Journal of Medicine, 2021
- Trends over time in adult cannabis use: A review of recent findingsCurrent Opinion in Psychology, 2021
- MDMA-related presentations to the emergency departments of the European Drug Emergencies Network plus (Euro-DEN Plus) over the four-year period 2014–2017Clinical Toxicology, 2020
- Psychedelics and Psychedelic-Assisted PsychotherapyAmerican Journal of Psychiatry, 2020
- Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016JAMA Psychiatry, 2020
- Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysisInternational Journal of Methods in Psychiatric Research, 2019
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequencesJournal of Psychopharmacology, 2016
- Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult populationJournal of Psychopharmacology, 2015
- Psychedelics and Mental Health: A Population StudyPLOS ONE, 2013